Nyxoah S.A.
NASDAQ:NYXHMedical - Instruments & Supplies
+$0.02 today
- Market cap
- $87.45M
- Beta
- 0.89
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$1.99
Volume 0.09M
Average 0.22M
Financial health
Nyxoah S.A. financial health
Start with the overall verdict and the rule-based risk checks for NYXH, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
The balance sheet looks mixed, so liquidity and debt trends deserve a closer read.
Cash & Investments
$27.83M
Debt Cushion
-$8.38M
Current Ratio
1.0x
Interest Coverage
Not available
Risk checks
7 of 10 checks flagged
Interest coverage
-31.4×
Passes when: Operating income is at least 1.5 times interest expense.
Manageable net debt
Negative EBITDA
Passes when: Net debt is below 3 times EBITDA.
Debt repayment from cash flow
Negative FCF
Passes when: Free cash flow could repay all debt within 5 years.
Altman Z-score trend
0.82 → -4.43
Passes when: The Z-score is stable or rising, or stays above 2.99.
Short-term liquidity
1.0×
Passes when: Current assets are at least 1 times current liabilities.
Tangible equity base
137.3%
Passes when: Goodwill and intangibles are below 50% of equity.
Share dilution
+16.1% per year
Passes when: Diluted share count grows no more than 2% per year.
Positive equity
Positive
Passes when: Shareholders’ equity is above zero.
Near-term debt coverage
1.5×
Passes when: Cash and short-term investments cover debt due within 12 months.
Debt growth versus revenue growth
52.4% vs. 48.1%
Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Average4 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Distress zone-3.89
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
| Score | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Piotroski F (0–9) | — | — | — | — | 4 | 2 | 1 | 2 | 2 |
| Altman Z | 31.97 | 31.25 | 13.27 | 10.24 | 12.69 | 1.66 | 0.24 | 0.82 | -4.43 |
Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$12.98M
Q1 2026
Quick Ratio
0.9x
Q1 2026
Current Ratio
1.0x
Q1 2026
Cash Ratio
0.3x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Working capital (Q1 2026)
-€492.86K
Current assets − current liabilities
Days sales outstanding
281 d
-216 days vs. prior year
Days inventory outstanding
460 d
-649 days vs. prior year
Days payables outstanding
1356 d
+474 days vs. prior year
Cash conversion cycle
-614 d
-1339 days vs. prior year
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$36.22M
Q1 2026
Debt/Equity
1.0x
Q1 2026
Debt/Assets
0.4x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Net debt
€10.18M
Total debt − cash − short-term investments
Net debt / EBITDA
Negative EBITDA
Above 3× is elevated
Free cash flow / debt
-202.3%
Share of debt one year of FCF could repay
Years to repay debt
Negative FCF
Total debt ÷ free cash flow
Operating cash flow / current liabilities
-1.7×
Above 1× funds a year of obligations
Interest coverage
-31.4×
Operating income ÷ interest expense
Debt maturity
Cash and short-term investments cover short-term debt 1.5×.
Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$1.80M
Q1 2026
Assets
$97.97M
Q1 2026
Liabilities
$61.96M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Claims on €97.97M in assets
- Payables12.9%
- Short-term debt17.6%
- Long-term debt17.9%
- Deferred revenue1.9%
- Other liabilities12.9%
- Equity36.8%
Goodwill + intangibles
€49.42M
50.4% of total assets
Share of equity
137.3%
Above 50% leaves little tangible backing
Tangible equity
-€13.42M
Equity left after writing off goodwill and intangibles
Deferred revenue
€1.84M
Customer prepayments: a liability settled by delivering service, not cash
Competitor health
How does Nyxoah S.A. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
OmniAb, Inc. OABI:NASDAQ | $716.17M | 0.08 | 0.07 | 0.12 | — | 4.02 | 4.02 | 1.57 |
Prenetics Global Limited PRE:NASDAQ | $279.64M | 0.01 | 0.01 | 0.93 | — | 2.76 | 3.01 | 1.16 |
OraSure Technologies, Inc. OSUR:NASDAQ | $249.95M | 0.04 | 0.03 | 3.27 | — | 5.80 | 6.58 | 5.01 |
Utah Medical Products, Inc. UTMD:NASDAQ | $205.05M | 0.00 | 0.00 | Net cash | — | 34.57 | 37.62 | 33.01 |
Invivyd, Inc. IVVD:NASDAQ | $171.58M | 0.01 | 0.01 | 4.45 | — | 6.50 | 7.24 | 6.64 |
KORU Medical Systems, Inc. KRMD:NASDAQ | $160.49M | 0.21 | 0.12 | 2.98 | — | 1.99 | 2.44 | 1.08 |
Protara Therapeutics, Inc. TARA:NASDAQ | $155.77M | 0.02 | 0.02 | 0.81 | — | 14.58 | 14.58 | 4.54 |
Perspective Therapeutics, Inc. CATX:AMEX | $113.89M | 0.01 | 0.01 | 0.29 | — | 5.17 | 5.17 | 1.07 |
Neuronetics, Inc. STIM:NASDAQ | $108.04M | 4.04 | 0.64 | Net cash | — | 1.87 | 2.02 | 1.12 |
Questions
Financial health questions
Common questions about NYXH's balance sheet, answered from the reported figures.
Is NYXH's balance sheet healthy?
Nyxoah S.A. (NYXH) has a current ratio of 0.99, a quick read on short-term liquidity.
How leveraged is NYXH?
Debt to equity is 1.01, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.